MaxCyte Stock

MaxCyte Capital Expenditures

Delisted

The Capital Expenditures (CapEx) of MaxCyte (MXCT) as of Aug 5, 2026 is -1.65 M USD. In the previous year, Capital Expenditures (CapEx) was -3.70 M USD — a change of -55.38% (higher).

Capital Expenditures

-1.65 MUSD

YoY

-55.38%

Last updated:

Capital Expenditures (CapEx) of MaxCyte is 2026 -1.65 M USD. Capital Expenditures (CapEx) of MaxCyte was 2025 -3.70 M USD. It decreases by -55.38% higher compared to the previous year.
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Capital Expenditures (CapEx) of MaxCyte is -1.65 M USD in 2026.

Capital Expenditures (CapEx) of MaxCyte changed from -3.70 M USD to -1.65 M USD, representing a -55.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s MaxCyte historically and in real time.

Access this data via the Eulerpool API

Cash Flow — MaxCyte

All Key Metrics — MaxCyte